CT-868
id:
ct-868-267-10028361
title:
CT-868
text:
CT-868 is an experimental "biased dual GLP-1 and GIP receptor modulator that exhibits no arrestin coupling or receptor internalization at either receptor". It is developed by Carmot Therapeutics for diabetes and obesity.
brand slug:
wiki
category slug:
encyclopedia
description:
original url:
https://en.wikipedia.org/wiki/CT-868
date created:
date modified:
2024-01-01T01:19:10Z
main entity:
image:
fields total:
13
integrity:
12